• Funds advised by SK Capital Partners, Bain Capital Life Sciences acquired a majority stake in Swixx Biopharma from HBM Healthcare Investments, other shareholders.
• HBM Healthcare Investments retained about an 8% stake in Swixx Biopharma following the closing of the transaction.
• Swixx founders, senior management stay invested. HBM, Mérieux Equity Partners continue board representation.
• Swixx, founded in 2014, positions the deal to accelerate expansion of its biopharma commercialization platform across additional geographies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2336356_de) on June 01, 2026, and is solely responsible for the information contained therein.